Abstract:Ensuring the quality and safety of biopharmaceutical products requires the effective separation of monoclonal antibodies (mAbs) from host cell proteins (HCPs). A major challenge in this field is the enzymatic hydrolysis of polysorbates (PS) in drug products. This study addresses this issue by investigating the removal of polysorbate‐degrading HCPs during the polishing steps of downstream purification, an area where knowledge about individual HCP behavior is still limited. We investigated the separation of different mAb formats from four individual polysorbate degrading hydrolases (CES1F, CES2C, LPLA2, and PAF‐AH) using cation exchange (CEX) and mixed‐mode chromatography (MMC) polishing steps. Our research identified a key challenge: The similar elution behavior of mAbs and HCPs during chromatographic separation. To investigate this phenomenon, we performed high‐throughput binding screenings for recombinant polysorbate degrading hydrolases and representative mAb candidates on CEX and MMC chromatography resins. We then employed a three‐step strategy that also served as a scale‐up process, optimizing separation conditions and leading to the successful removal of specific HCPs while maintaining high mAb recovery rates (>96%). This strategy involved the use of surface response models and miniature columns for screening, followed by validation on larger columns using a chromatography system. Our results highlight the critical role of the inherent properties of mAbs for successful separation from HCPs. These results underscore the need to tailor the purification process to leverage the slight differences in binding behavior and elution profiles between mAbs and specific HCPs. This approach lays the foundation for developing more effective strategies for overcoming the challenge of enzymatic polysorbate degradation, paving the way for improved quality and safety in biopharmaceutical products.

Methods for addressing host cell protein impurities in biopharmaceutical product development

Chromatographic technology in antibody purification and its progress

UV/Vis-based process analytical technology to improve monoclonal antibody and host cell protein separation

Host cell proteins in monoclonal antibody processing: Control, detection, and removal

Effective strategies for host cell protein clearance in downstream processing of monoclonal antibodies and Fc-fusion proteins

Host cell protein impurities in chromatographic polishing steps for monoclonal antibody purification

Identification and characterization of CHO host-cell proteins in monoclonal antibody bioprocessing

Identification and classification of host cell proteins during biopharmaceutical process development

A novel approach to monitor clearance of host cell proteins associated with monoclonal antibodies

Towards continuous mAb purification: Clearance of host cell proteins from CHO cell culture harvests via “flow‐through affinity chromatography” using peptide‐based adsorbents

Targeted CHO cell engineering approaches can reduce HCP‐related enzymatic degradation and improve mAb product quality

Analysis of Host Cell Proteins in Monoclonal Antibody Therapeutics Through Size Exclusion Chromatography

Tailoring polishing steps for effective removal of polysorbate‐degrading host cell proteins in antibody purification

Optimized Sample Preparation and Data Processing of Data-Independent Acquisition Methods for the Robust Quantification of Trace-Level Host Cell Protein Impurities in Antibody Drug Products

Host cell protein profiling of commercial therapeutic protein drugs as a benchmark for monoclonal antibody-based therapeutic protein development

Technical Optimization for the High-Throughput Purification of Antibodies on Automated Liquid Handlers

Two major mechanisms contributing to copurification of CHO host cell proteins and strategies to minimize their negative impact

Improved clearance of host cell protein impurities at the polishing purification step using multimodal chromatography

Identification and Quantification of a Problematic Host Cell Protein to Support Therapeutic Protein Development.

Technical advancement and practical considerations of LC-MS/MS-based methods for host cell protein identification and quantitation to support process development

Optimizing high throughput antibody purification by using continuous chromatography media